Hitting a weight loss plateau can feel like hitting a wall. You have been consistent with your treatment, following your doctor’s guidance, and watching the numbers drop — then suddenly, the scale stops moving. If you are currently on Wegovy 2.4mg and your weight has remained stagnant for weeks or months, take heart: a new option is on the way.
Wegovy 7.2mg — a higher-dose formulation of semaglutide — is showing promising results in clinical trials for patients who have reached a plateau on the standard 2.4mg maintenance dose. Here is what the research tells us and how eligible patients in Singapore may access this treatment.
Why Weight Loss Plateaus Happen
A weight loss plateau is not a sign of failure. It is a well-documented physiological phenomenon. As the body sheds weight, several adaptive mechanisms kick in:
- Metabolic adaptation: Your resting metabolic rate drops as you lose weight — sometimes more than expected for your new body size. Your body becomes more efficient, burning fewer calories for the same activities.
- Hormonal shifts: Weight loss increases ghrelin (the hunger hormone) and decreases leptin (the satiety hormone). Your brain receives stronger hunger signals and weaker fullness signals.
- Energy conservation: Non-exercise activity thermogenesis (NEAT) — the calories you burn through fidgeting, standing, and daily movement — tends to decrease unconsciously.
These mechanisms evolved to protect us during periods of food scarcity. They are not a personal failing — they are biology. The question for patients on Wegovy 2.4mg is: can a higher dose help overcome these adaptive barriers?
What Is Wegovy 7.2mg?
Wegovy 7.2mg is an investigational higher dose of semaglutide — three times the currently approved 2.4mg maintenance dose. It uses the same active ingredient (semaglutide, a GLP-1 receptor agonist) at a higher concentration. The higher dose is being studied specifically for patients who have demonstrated tolerance to the 2.4mg dose but whose weight loss has plateaued.
Important: Wegovy 7.2mg is not yet commercially available in Singapore pharmacies. It is currently accessible through the Health Sciences Authority (HSA) Named Patient Programme, which permits registered medical clinics to import unregistered therapeutic products for specific patients under medical supervision.
The STEP UP Trial: What the Data Shows
The STEP UP trial was a Phase 3 clinical study conducted between January 1, 2023, and November 26, 2024. It evaluated the efficacy and safety of semaglutide 7.2mg compared to semaglutide 2.4mg and placebo in adults with obesity or overweight with at least one weight-related comorbidity.
Key findings among participants who were fully adherent to the treatment protocol and accompanying lifestyle modifications:
- Average weight loss of up to 20.7% of baseline body weight on Wegovy 7.2mg
- An additional 3% weight reduction for patients whose weight had plateaued under Wegovy 2.4mg
- Meaningful improvements in cardiometabolic risk factors including waist circumference, blood pressure, and glycemic control
To put these numbers in perspective: for a patient weighing 100kg, a 20.7% reduction represents a loss of 20.7kg. The additional 3% — triggered when switching from 2.4mg to 7.2mg after a plateau — represents a further 3kg of weight reduction beyond what the standard dose had already achieved.
| Metric | Wegovy 2.4mg | Wegovy 7.2mg |
|---|---|---|
| Average weight loss (fully adherent) | ~17.5% | Up to 20.7% |
| Additional loss after plateau | — | ~3% beyond 2.4mg results |
| Study period | January 1, 2023 – November 26, 2024 | |
| Trial | STEP UP (Phase 3) | |
Who May Be Eligible for Wegovy 7.2mg?
Wegovy 7.2mg through the Named Patient Programme is being considered for patients who:
- Are currently on Wegovy 2.4mg and tolerating the treatment well
- Have experienced a sustained weight plateau (typically 8–12 weeks or more) despite adherence to treatment and lifestyle recommendations
- Have no significant tolerability issues at the 2.4mg dose
- Are under the ongoing care of a qualified medical practitioner
This is not a starting dose for new patients. Individuals new to GLP-1 receptor agonist treatment begin at lower doses and titrate upward under medical supervision.
Accessing Wegovy 7.2mg Through the HSA Named Patient Programme
Accord Medical Clinic is one of the few clinics in Singapore directly importing Wegovy 7.2mg under the HSA Named Patient Programme.
The Named Patient Programme is a regulated HSA pathway that allows registered medical practitioners to import unregistered therapeutic products for individual patients when there is a clinical need that cannot be met by registered alternatives. The importing clinic handles the entire process:
- Medical assessment: The doctor evaluates your medical history, current treatment, and plateau status
- HSA application: The clinic submits the necessary documentation to HSA for approval
- Product shipment: Once approved, the medication is ordered and shipped from the manufacturer
- Clinic delivery: The medication arrives at our clinic, and you are notified for collection and administration
Patients do not need to handle any HSA paperwork — the clinic manages the entire process.
What to Expect: The Import Timeline
The overall process of importing Wegovy 7.2mg — including HSA approval, product shipment, and delivery to our clinic — may take up to eight weeks.
| Stage | What Happens | Estimated Duration |
|---|---|---|
| 1. Medical Consultation | Doctor assesses suitability and reviews your medical history | Same day |
| 2. HSA Application | Clinic submits the Named Patient Programme application | 2–4 weeks |
| 3. Product Shipment | Medication ordered and shipped from the manufacturer | 2–3 weeks |
| 4. Clinic Delivery | Medication arrives at the clinic; patient is notified | 1 week |
| Total estimated timeline | ~8 weeks | |
Safety and Side Effects
The STEP UP trial evaluated the safety profile of the 7.2mg dose. As with any dose escalation of a GLP-1 receptor agonist, the most commonly reported side effects were gastrointestinal — including nausea, vomiting, diarrhoea, and constipation. These were generally mild to moderate in severity and tended to diminish over time as the body adjusted.
Medical supervision is essential for any dose adjustment. The decision to escalate must be made by a doctor who knows your full medical history and treatment goals.
Frequently Asked Questions
Is Wegovy 7.2mg approved by the HSA?
Wegovy 7.2mg is not yet registered as a commercial product with the HSA. It is accessible through the Named Patient Programme, a regulated pathway for importing unregistered therapeutic products when clinically indicated.
How much additional weight loss can I expect on 7.2mg?
The STEP UP trial demonstrated an average additional weight loss of approximately 3% for patients whose weight had plateaued on Wegovy 2.4mg. Individual results vary based on adherence, lifestyle factors, and metabolic response.
Can I switch directly from Wegovy 2.4mg to 7.2mg?
Dose escalation is determined by your doctor based on your individual assessment. The transition follows a medically supervised titration schedule.
What if I am not currently on Wegovy 2.4mg?
Wegovy 7.2mg is being studied for patients already on the 2.4mg maintenance dose. If you are new to medical weight management, your doctor will recommend the most appropriate starting point — typically beginning at 0.25mg and titrating upward.
Is the 7.2mg dose safe?
STEP UP trial data indicate a safety profile consistent with the known effects of GLP-1 receptor agonists at therapeutic doses. Side effects, where they occur, are typically mild to moderate and manageable under medical supervision.
How do I find out if I am eligible?
Book a consultation at Accord Medical Clinic. Our doctor will review your treatment history, assess your plateau status and tolerability, and determine whether Wegovy 7.2mg through the Named Patient Programme is appropriate for you.
Who handles the HSA paperwork?
Accord Medical Clinic manages the entire HSA Named Patient Programme application process on your behalf. You do not need to submit any documents to HSA directly.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Wegovy (semaglutide) is a prescription-only medicine that must be prescribed by a registered medical practitioner. Always consult a qualified healthcare professional for medical concerns, diagnosis, or treatment. Individual results vary. The STEP UP trial data referenced is from published clinical research.
Interested in Wegovy 7.2mg?
Accord Medical Clinic is one of the few clinics in Singapore directly importing Wegovy 7.2mg under the HSA Named Patient Programme.
Please WhatsApp us at 98465594 if you are interested in Wegovy 7.2mg. Our team will guide you through the process, including the initial medical consultation, HSA application, and treatment timeline (up to eight weeks).
Accord Medical Clinic
📍 Block 325 Ubi Avenue 1 #01-701, Singapore 400325
📞 6844 1528
📧 accordmedicalsg@hotmail.com